If you are looking for big potential returns, then Mesoblast Ltd shares could be worth considering.
Investors familiar with the journey of Ryoncil through the FDA will be painfully aware of the delays to commercialisation, attributable at least in part, to perceived shortcomings in the then potency assays.
The assay will be part of a quality control matrix for the release of each batch of Ryoncil in conjunction with the existing potency assays for IL-2Ra inhibition and CAP.
Based on its current share price of $2.16, this implies potential upside of 106% for investors over the next 12 months.
4 sentences from our version of the report,
chosen to cover it. Nothing here is written; every line is in the article below.
How
Headline check
One of the three things this headline claims did not turn up in the report.
The figure “100%” is in the headline. We could not find it in the report.
Figures, names and quoted words in the headline, looked for in the report itself — not in the summary above. Figures are matched digit for digit, so a report that writes “forty per cent” out in words where the headline wrote “40%” is queried here when it should not be. How this is checked
library pictureNot from this story. A library photograph of
stock market trading screens, used to illustrate it.
Market centre in Tokyo stock exchange
ehnmark / Wikimedia Commons, CC BY
The article, shortened and in plain language
If you are looking for big potential returns, then Mesoblast Ltd shares could be worth considering.
Bell Potter notes that the US FDA has approved an additional potency assay for Ryoncil.
Investors familiar with the journey of Ryoncil through the FDA will be painfully aware of the delays to commercialisation, attributable at least in part, to perceived shortcomings in the then potency assays. Potency measurement is complex in a biological asset, where the starting material may differ from batch to batch and with a multifactorial mechanism of action.
The assay will be part of a quality control matrix for the release of each batch of Ryoncil in conjunction with the existing potency assays for IL-2Ra inhibition and CAP.
According to the note, in response to the news, the broker has retained its buy rating and $4.45 price target on Mesoblast shares.
Based on its current share price of $2.16, this implies potential upside of 106% for investors over the next 12 months.
Shortened to 1 minute
of reading, this version reads 10.9 on the Niral Score.
You are reading our version, not theirs.
This is The Motley Fool Australia's report shortened to its most important sentences, in plainer words, with
verdicts and loaded words taken out. Plain description stays, and so do adjectives
that carry a fact, such as "former" or "federal". The reporting, the facts and the quotations
are theirs — quotations are never edited — and the indicators beside it measure
this version. Hover or tap Adjectives to see every one left in the text.
How this outlet filed it, and how we rewrote it
No other newsroom we read has filed on this event, so there is nothing to compare it with yet.
Readers can ask a question about this story here.
Questions and answers are for subscribers.
Sign in
to read them.
Comments are read before they appear where anything in them needs a person to look.
Nothing posted here is ever deleted; a comment taken down keeps its text and the reason,
so the decision can be looked at again. How this works
